CA1

Carbonic anhydrase 1 · P00915 · CA1 on Sugi Atlas →

1,280,692 patent compounds predicted against CA1, 666,437 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Benzenesulfonamide (SCHEMBL729)	1.00	16/20
Busulfan (SCHEMBL4373)	0.50	16/20
Improsulfan (SCHEMBL8954)	0.35	16/20
SCHEMBL3354	0.67	15/20
Edetic Acid (SCHEMBL1373)	0.40	15/20
Edetic Acid (SCHEMBL905)	0.39	15/20
Sulfanilamide (SCHEMBL740)	1.00	14/20
Benzoic Acid (SCHEMBL823)	0.59	14/20
SCHEMBL8588	0.48	12/20
SCHEMBL7369	0.56	11/20
SCHEMBL3353	0.61	10/20
Sodium Lauryl Sulfate (SCHEMBL1102)	0.59	10/20
SCHEMBL7434	0.53	10/20
SCHEMBL14485	0.53	10/20
Probenecid (SCHEMBL3663)	0.69	9/20
SCHEMBL9577	0.64	9/20
Methylparaben (SCHEMBL4440)	1.00	8/20
P-Toluenesulfonamide (SCHEMBL7370)	1.00	8/20
Coumarin (SCHEMBL6252)	1.00	7/20
Phenylmethanesulfonamide (SCHEMBL7371)	1.00	7/20

Clinical trials — most relevant to CA1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Multi-level Life-span Characterization of Adult-depression and Effects of Medication and Exercise	PHASE4	COMPLETED
Enhanced MRI Imaging in Healthy Participants and Participants With Epilepsy	PHASE2	RECRUITING
Amiloride Hydrochlorothiazide as Treatment of Acute Inflammation of the Optic Nerve	PHASE2	UNKNOWN
Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment	PHASE2	COMPLETED
Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens for the Treatment of Potentially Hazardous Colorectal Cancer SD Status	PHASE2	RECRUITING
Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease	PHASE2	COMPLETED
Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers	PHASE1	COMPLETED
Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent Glioblastoma	EARLY_PHASE1	RECRUITING
The Etiology and Progression of Brain Tumors	nan	COMPLETED
Studying Tumor Tissue Samples From Patients Who Have Undergone Surgery for Localized Kidney Cancer	nan	WITHDRAWN
Study of Cerebrospinal Fluid Samples in Diagnosing Carcinomatous Meningitis in Patients With Cancer or Meningeal Syndrome	nan	UNKNOWN
Neurological Prognostication of Patients in Therapeutic Hypothermia After Cardiac Arrest	nan	COMPLETED
Multimodal Monitoring of Cerebral Autoregulation After Pediatric Brain Injury	nan	COMPLETED
Wolfram Syndrome and WFS1-related Disorders International Registry and Clinical Study	nan	RECRUITING
Search for Genes Influencing Childhood Absence Epilepsy (CAE) Study	nan	COMPLETED
A Longitudinal Study to Analyse the Correlation Between CAI and Bilirubin	nan	UNKNOWN
Selecting Hypoxic Tumours for Treatment Modification	nan	RECRUITING
The Neuroprotective Effect of Dexmedetomidine Preserving Brain Functional Connectivity in Elderly Patients	nan	COMPLETED
The Canadian Multicentre CSF Monitoring and Biomarker Study	nan	COMPLETED
Implication of Long Non-coding RNA CCDC144NL-AS1/Micro RNA-143-3p Axis Expression Level as Novel Signature in Colorectal Cancer	nan	COMPLETED
Improving Safety in Pediatric Thyroidectomy by PTH Measurements	nan	COMPLETED
Study of Pathophysiology of Status Epilepticus and Dysimmune Encephalitis	nan	RECRUITING
Symptom Evaluation After Cessation of a Proton Pump Inhibitor in Healthy Volunteers	nan	COMPLETED
Potential Synergistic Effect of Combined Blood Flow Restriction Training and Betaine Supplementation on Skeletal Muscle	nan	COMPLETED
Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease	nan	COMPLETED
Multicenter Study of 18F-Labeled NY104 for PET/CT Imaging in Renal Cell Carcinoma	nan	RECRUITING
Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis Complex	nan	UNKNOWN
The Energetic Origin of Neurodegeneration in MS	nan	COMPLETED
Calciotropic Effects After HCG Stimulation Test	nan	COMPLETED
Radiomics: a Study of Outcome in Lung Cancer	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CA1 binder may also engage these)

Protein	Name	Similarity
P35217	—	1.000	P35217 →
P00916	—	1.000	P00916 →
Q8HY33	—	1.000	Q8HY33 →
Q7M317	—	0.998	Q7M317 →
Q7M316	—	0.997	Q7M316 →
B0BNN3	—	0.996	B0BNN3 →
Q1LZA1	—	0.995	Q1LZA1 →
P13634	—	0.995	P13634 →
Q8UWA5	—	0.993	Q8UWA5 →
P00920	—	0.990	P00920 →
P00917	—	0.988	P00917 →
P00919	—	0.988	P00919 →
Q5S1S4	—	0.987	Q5S1S4 →
P07452	—	0.986	P07452 →
P00921	—	0.986	P00921 →
Q3SZX4	—	0.986	Q3SZX4 →
CA2	Carbonic anhydrase 2	0.985	landscape →
P83299	—	0.984	P83299 →
P48282	—	0.984	P48282 →
CA3	Carbonic anhydrase 3	0.983	landscape →
Q92051	—	0.982	Q92051 →
P27139	—	0.982	P27139 →
P07630	—	0.981	P07630 →
Q9D6N1	—	0.977	Q9D6N1 →
P07450	—	0.977	P07450 →
P16015	—	0.977	P16015 →
P00922	—	0.976	P00922 →
CA7	Carbonic anhydrase 7	0.975	landscape →
CA13	Carbonic anhydrase 13	0.974	landscape →
Q9ERQ8	—	0.972	Q9ERQ8 →